Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurélien Marabelle(Institut Gustave Roussy), Marwan Fakih(City of Hope), Juanita Lopez(Royal Marsden NHS Foundation Trust), Manisha H. Shah(The Ohio State University), Ronnie Shapira‐Frommer(Sheba Medical Center), Kazuhiko Nakagawa(Kindai University), Hyun Cheol Chung(Yonsei University), Hedy L. Kindler(University of Chicago), José A. López-Martín(Research Institute Hospital 12 de Octubre), Wilson H. Miller(Jewish General Hospital), Antoîne Italiano(Institut Bergonié), Steven Kao(Chris O’Brien Lifehouse), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Jean‐Pierre Delord(Institut Claudius Regaud), Robert R. McWilliams(Mayo Clinic in Arizona), David Fabrizio(Foundation Medicine (United States)), Deepti Aurora-Garg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lei Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fan Jin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin Norwood(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yung‐Jue Bang(Seoul National University)
Cited by 2,472Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis